58 results about "Liposome membrane" patented technology

The invention discloses a compound liposome, a freeze-dried powder injection as well as a preparation method and application of the freeze-dried powder injection. The compound lipidosome comprises a lipidosome membrane and an inner water phase encapsulated in the lipidosome membrane, the paclitaxel palmitate is encapsulated in a lipid bilayer of the liposome membrane; the gemcitabine or the salt thereof is encapsulated in the inner water phase; the compound liposome comprises the following raw materials: paclitaxel palmitate, lecithin, a polyethylene glycol derivative, gemcitabine or a salt thereof, an organic solvent and a buffer solution A; the molar ratio of the lecithin to the polyethylene glycol derivative is 1: (0.01-0.15). The compound liposome disclosed by the invention is relatively high in encapsulation efficiency (especially the encapsulation efficiency of PTX-PA is relatively good) and relatively high in safety, the preparation method is simple and easy to operate, the industrialization degree is high, and the prepared compound liposome has a relatively good long-circulation effect, a relatively good anti-tumor effect and good in-vivo tolerance.

The invention discloses a method for preparing a heterozygous exosome through DNA zipper mediated membrane fusion. A DNA zipper structure (ZDC / cZDC) modified by cholesterol is designed and anchored to the surface of a BMSC source exosome and the surface of a lipidosome membrane loaded with siRNA, membrane fusion is achieved through DNA complementary pairing, and after DNase I enzymolysis, the heterozygous exosome carrying siRNA and over-expressed CD146 at the same time is obtained. The method has the advantages of high fusion efficiency and uniform particle size, solves the problems of low drug loading efficiency and poor targeting property of the traditional exosome, and is suitable for gene-drug collaborative delivery.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a vitamin C lipidosome wrapping composition and a preparation method thereof.The vitamin C lipidosome wrapping composition comprises lipidosome, and the lipidosome comprises a main membrane material and auxiliary components; the HSPC and the DPPC synergistically improve the liposome membrane compactness and reduce drug leakage, the active loading of vitamin C is driven by a pH gradient method (the pH of an external water phase is 4.0-the pH of an internal water phase is 7.4), the encapsulation efficiency is improved to 92% or above, and the particle size of the liposome is controlled to be 100 + / -20 nm and PDI is controlled to be smaller than or equal to 0.15 through combination of high-pressure homogenization and ultrasound.

The invention discloses an irinotecan and afatinib maleate co-loaded liposome preparation as well as a preparation method and application thereof, irinotecan and afatinib maleate are taken as effective components of the liposome, and the liposome comprises a liposome carrier, an inner water phase positioned in a liposome membrane and an outer water phase positioned outside the liposome membrane; the irinotecan and the afatinib maleate are encapsulated in the inner water phase; the inner water phase comprises an ammonium salt aqueous solution, and an ammonium salt gradient exists between the inner water phase in the liposome membrane and the outer water phase outside the liposome membrane; the outer water phase is a physiological isotonic solution. According to the present invention, the research results show that the irinotecan and afatinib maleate co-carrying liposome can simultaneously deliver the two drugs with the synergistic ratio into the same tumor cell compared to the irinotecan single drug liposome and the afatinib maleate single drug liposome so as to maximize the synergistic effect of the drugs, and significantly improve the anti-tumor effect;

The application belongs to the technical field of biological medicine, and particularly relates to a nano delivery system based on exosome membrane fusion and a preparation method and application thereof, which comprises: (1) a prodrug complex formed by paclitaxel (PTXL) and IR780; (2) a liposome core loaded with the prodrug complex, and a membrane material of the liposome core comprises: DSPE-PEG-MAP, DSPE-PEI, phospholipid and cholesterol; and (3) a homologous tumor cell-derived exosome membrane fused to the surface of the liposome core. The application realizes the design of multi-level delivery in the same nanoparticle by means of the optimization of the properties of the liposome membrane composition, the fusion of the exosome and the liposome membrane, the mixed biomimetic nanoparticle particle size, the preparation of the PTXL targeted prodrug and the like, so as to improve the treatment effect at different levels.

The application provides a paclitaxel liposome injection and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The injection is prepared from the following injection-grade raw and auxiliary materials: paclitaxel, phospholipid, cholesterol, gamma-aminobutyric acid, potassium lactate, a buffer, a freeze-drying protective agent and water for injection. The gamma-aminobutyric acid and the potassium lactate are simultaneously added as the liposome membrane stabilizer, the two synergistically act, the compactness and the stability of the lipid bilayer are significantly enhanced, the paclitaxel encapsulation rate is improved, the drug leakage rate is reduced, and the long-term storage stability of the preparation is improved.

The invention discloses a cholesterol modified double-stranded DNA membrane skeleton liposome delivery system and a preparation method and application thereof, and belongs to the technical field of drug delivery. The system is composed of cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine modified by methoxy polyethylene glycol and double-stranded DNA (chol-dsDNA) modified by 5 '-cholesterol, and the chol-dsDNA is anchored on the inner side and the outer side of a liposome membrane through a hydrophobic effect to form a bionic skeleton. The system is excellent in mechanical stability, low in drug leakage rate, high in tumor targeted enrichment capacity and good in biocompatibility, can efficiently entrap irinotecan hydrochloride and other hydrophilic drugs, is used for tumor treatment, and is simple and convenient to prepare and easy to scale.

The invention discloses a multifunctional double-drug delivery system based on metal collaborative treatment and application of the multifunctional double-drug delivery system, and belongs to the technical field of biological medicine. The double-drug delivery system is double-drug delivery lipidosome and comprises metal ions, a lipidosome membrane and active ingredients, the metal ions are adsorbed on the surface of the lipidosome membrane, and the active ingredients are wrapped in the lipidosome membrane; the metal ions are divalent metal ions; the active component consists of an STING agonist and a traditional Chinese medicine active monomer component. According to the double-drug delivery system, the STING agonist and the traditional Chinese medicine anti-inflammatory components are co-loaded through lipidosome, and multi-dimensional remodeling of a tumor microenvironment is achieved through the double effects of exciting tumor immunity and inhibiting inflammatory reaction; and meanwhile, by introducing metal ions, the lysosome escape efficiency of a liposome drug delivery system is effectively enhanced, so that the intracellular delivery efficiency of the drug is improved.

Tolerogenic liposome-based compositions and uses thereof for treating immune disorders. The compositions include two populations of liposomes. The first population of liposomes has a size in the range from 2 to 200 nm, and the second population of liposomes has a size in the range from 500 to 2000 nm. The liposomes of the first and second populations carry one or more antigens. The liposomal membrane of each liposome in the first and second liposome populations include phosphatidylserine in an amount ranging from 20 to 60% by weight with respect to the total composition of the liposome's membrane.

The invention discloses a transrespiratory tract noninvasive drug delivery carrier and a preparation method and application thereof.The transrespiratory tract noninvasive drug delivery carrier comprises a lipid bimolecular layer and bioactive ingredients wrapped in the lipid bimolecular layer, and the lipid bimolecular layer comprises a liposome membrane and an enzyme responsive modification part embedded into the liposome membrane; the enzyme responsive modification part is a substrate polypeptide capable of being degraded by RTC-enz and polyethylene glycol connected with the substrate polypeptide. According to the invention, an enzyme-responsive modification part is introduced to the surface of a liposome membrane, so that efficient targeted disintegration of the liposome membrane is realized in pulmonary alveoli in an RTC-enz environment. Bioactive components carried by the liposome are uniformly distributed on the surface of a'gas-blood barrier 'in the pulmonary alveolus after the liposome is disintegrated, so that effective retention and uniform dispersion can be realized, and the condition that the liposome which cannot be disintegrated blocks a'gas-liquid' barrier on the surface of the pulmonary alveolus at the end of the respiratory tract is avoided; and potential toxicity caused by transfection of bioactive components carried by liposome which cannot be disintegrated into alveolar epithelial cells is also avoided.

An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition, in which liposomes encapsulate a drug, with a platinum preparation. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) a platinum preparation, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin; and cholesterols, the liposome composition includes a drug and has an inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the platinum preparation are administered simultaneously or sequentially.

An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition in which liposomes encapsulate a drug with an immune checkpoint inhibitor. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin, and cholesterols, the liposome composition includes a drug and has art inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.

The invention discloses a chitosan modified turmeric-broccoli exosome hybrid nasal spray and application thereof, and belongs to the technical field of biological medicine and drug delivery. The nasal spray is formed by dispersing double plant exosome-lipidosome hybrids in a carrier for nasal cavities. The preparation method comprises the following steps: fusing curcumin carried by a turmeric exosome and sulforaphane carried by a broccoli bud exosome with a pH response liposome membrane containing 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine, and modifying by chitosan to form a three-layer structure; the preparation method comprises the steps of exosome extraction, ultrasonic drug loading, liposome hybridization, chitosan coating and preparation blending. The nasal spray is high in entrapment efficiency and uniform in particle size, the chitosan enhances nasal adhesion, inflammation targeted drug release is achieved through pH response, the brain targeting efficiency and stability are excellent, and the adaptability to children is good. The curcumin and sulforaphane are used for targeted therapy of children autism spectrum disorder neuroinflammation, anti-inflammation and anti-oxidation are achieved through synergism of curcumin and sulforaphane, the curative effect is remarkable, and a new scheme is provided for treatment of related diseases.

The invention relates to a process for obtaining an amphotericin B (AmB) formulation in liposomes containing dicetyl phosphate (DCP), based on incorporation of the drug into the membrane of preformed liposomes, combining the effects of pH on the solubility of amphotericin B and of temperature on the insertion of the drug into the liposome membrane. The technology also relates to use of the process and of the formulation for the manufacture of medicaments for the treatment of leishmaniasis and sporotrichosis, for oral or topical administration.

Disclosed herein is a biomimetic torpedo that can circumvent existing hurdles for RNA therapies. That is, RNA therapeutics can be harbored inside a torpedo shell made of neutrophil membranes in hybrid with a liposome membrane, which enables lesion targeting and shielding from immunogenicity. Further disclosed herein is a biomimetic targeting system that involves a neutrophil cell membrane capsule that encapsulates a therapeutic RNA.

This invention belongs to the field of ultrasound contrast microbubble synthesis technology, and relates to a method for preparing and applying ultrasound contrast microbubbles targeting CD93 molecules in tumor vascular endothelium. The method includes the following steps: constructing a recombinant expression vector capable of expressing the CD93 ligand MMRN2 protein, transfecting cells, and extracting the cell membrane using differential centrifugation; mixing dipalmitoylphosphatidylcholine, distearate phosphatidylethanolamine-polyethylene glycol 2000, and chloroform, adding DiI, and preparing a liposome membrane using a thin-film hydration method; mixing the cell membrane and the liposome membrane, performing ice-bath sonication, and mixing and shaking with perfluoropropane to obtain an ultrasound contrast agent targeting CD93 molecules in tumor vascular endothelium. The ultrasound contrast microbubbles prepared by the method of this invention have good biocompatibility compared to conventional antibody-targeting strategies, and can also improve stability and targeting, thereby enabling the assessment of CD93 molecule expression in tumors.

The present invention belongs to the technical field of enzyme preparations for feed, and discloses a processing method and application for improving the heat and acid resistance of enzyme preparations. The processing method of the present invention is as follows: the biofilm material is melted, stirred evenly and ultrasonicated to obtain a liposome film; an enzyme preparation and an emulsifier are added to the liposome film, fully mixed and ultrasonicated to obtain an enzyme preparation-liposome mixed solution; the temperature of the obtained enzyme preparation-liposome mixed solution is suddenly reduced to room temperature, and high-pressure centrifugal spray is performed to obtain a powdered enzyme preparation-liposome. The present invention utilizes a method for encapsulating the enzyme preparation with unilamellar liposomes to ensure that the enzyme preparation is isolated from the external environment, prevents it from oxidative deterioration, prolongs its active time, can improve the adaptability of the enzyme preparation to the environment, enhances the tolerance of the enzyme preparation to temperature and gastric acid, and is suitable for the processing and production of enzyme preparations for feed.

The invention belongs to the technical field of medicines, and particularly relates to construction and application of a size-variable liposome. The size-variable liposome TF-5 NP is characterized in that the size-variable liposome TF-5 NP is prepared from the following components: DSPE-PEG-bis-5HT and a liposome membrane structure. The innovative liposome for treating myocardial infarction is constructed, drugs are delivered to an inflammation microenvironment in a targeted mode, intelligent size adjustment, efficient encapsulation and slow release, remarkable improvement of cardiac functions, anti-inflammation and angiogenesis promotion are achieved, the treatment effect is achieved, examples and strategies are provided for treatment of myocardial infarction and related diseases, and the novel liposome has a wide application prospect. The development of cardiovascular disease treatment is promoted.

The invention discloses a compound liposome as well as a preparation method and application thereof. The compound lipidosome comprises a lipidosome membrane and an inner water phase encapsulated in the lipidosome membrane, the paclitaxel palmitate is encapsulated in a lipid bilayer of the liposome membrane; irinotecan hydrochloride is encapsulated in the inner water phase; the raw materials of the paclitaxel palmitate sustained-release tablet comprise the following components: 0.1-1.0% of 0.05 to 1.0 percent of irinotecan hydrochloride; 2-20% of a phospholipid; 0 to 0.3% of cholesterol; 0 to 0.2 percent of DSPE-mPEG2000 (Distearoyl Phosphate 50 to 400 mmol / L of an anionic precipitator; 0-40% of a freeze-drying protective agent; and water for injection; the percentage represents the percentage of the mass of each component in the total volume of all the raw materials, and the molar concentration is obtained by calculating the total volume of all the raw materials; the medicine-fat ratio in the raw materials is 1: (5-30); the medicine fat ratio is the ratio of the mass sum of paclitaxel palmitate and irinotecan hydrochloride to the mass sum of phospholipid and cholesterol. The compound liposome is high in encapsulation efficiency and uniform in particle size; in practical application, the compound has a synergistic anti-tumor effect and relatively low biotoxicity.

The application belongs to the field of biological medicine, and discloses a nano-lipid preparation for loading perfluorohexane and an antioxidant, wherein the nano-lipid preparation is a core-shell structure, the core-shell structure takes a phospholipid liposome membrane layer as an outer shell, and perfluorohexane and the antioxidant loaded in the outer shell serve as an inner core; the phospholipid liposome membrane layer is made of hydrogenated lecithin, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and cholesterol; and the application discloses an application of the nano-lipid preparation for loading perfluorohexane and the antioxidant in preparation of a medicine for treating myocardial infarction. The nano-lipid preparation has a suitable particle size, can be passively targeted and enriched to a myocardial infarction site, is stable, has a high encapsulation efficiency, and has a simple administration mode; after the lipid preparation is taken by myocardial cells, oxygen and the antioxidant are released, the oxygen can relieve an anoxic condition of a myocardial ischemia site, and the antioxidant can reduce ROS damage, both of which play a synergistic role, improve the survival rate of ischemic myocardial cells, and improve heart function.

The invention belongs to the technical field of liposome pharmaceutical preparations, and particularly relates to a liposome and application thereof, a liposome preparation and a preparation method and application thereof. The invention provides a liposome. A glutathione group and an indole residue are modified on a liposome membrane. The lipidosome provided by the invention has excellent transmembrane transport capacity, can efficiently penetrate through a blood-brain barrier and can be taken by glioma cells, and also shows excellent endosome escape characteristic, so that the technical problem of low blood-brain barrier transmittance in the glioma treatment process of temozolomide is effectively solved. Meanwhile, the invention provides a liposome preparation, the delivery efficiency and the anti-tumor curative effect are improved, the liposome preparation has an inhibiting effect on human / mouse glioma cells, the wide clinical application potential is shown, and an efficient and low-toxicity novel treatment scheme is provided for glioma patients.

The invention belongs to the technical field of biological detection, and relates to a synchronous detection sensor for small extracellular vesicle membrane proteins PD-L1 and miRNA-21 based on aptamer mediated membrane fusion and application of the synchronous detection sensor. The sensor comprises (1) a multifunctional liposome, a hairpin probe H1 and a hairpin probe H2 are encapsulated in the liposome, the surface of a liposome membrane is modified with an EpCAM nucleic acid aptamer and an auxiliary chain, and miRNA-21 in small extracellular vesicles, the hairpin probe H1 and the hairpin probe H2 form a first catalytic hairpin self-assembly system; (2) AptPD-L1-L with a hairpin structure, the AptPD-L1-L comprises a PD-L1 nucleic acid aptamer, a connecting arm, an auxiliary chain hybridization region and a partial excitation chain sequence which are sequentially connected from the 5'end to the 3 'end, and the partial excitation chain sequence and the 5' end of the auxiliary chain jointly form an excitation chain; and (3) a hairpin probe H3, a hairpin probe H4, the AptPD-L1-L, the auxiliary chain, the hairpin probe H3 and the hairpin probe H4 form a second catalytic hairpin self-assembly system. According to the invention, synchronous detection of miRNA-21 and membrane protein PD-L1 in sEVs is realized, and a new technical platform is provided for lung cancer liquid biopsy.

The invention relates to a preparation method and application of a novel tumor vaccine of targeted nano-liposomes, and the preparation method of the novel tumor vaccine of targeted nano-liposomes comprises the following steps: firstly, according to an HLA typing result of SK-BR-3, screening out dominant virus peptides from an HPV virus peptide library and literatures through antigen affinity prediction software; as one of the components wrapped in the lipidosome; the preparation method comprises the following steps: firstly, preparing an HER2 monoclonal antibody, then wrapping dominant virus peptide and an STING agonist into a liposome membrane material through a membrane dispersion method, and coupling with the HER2 monoclonal antibody to prepare the vaccine, so that the particle size of the finally obtained drug liposome is about 70nm, the particle size is uniform, the encapsulation efficiency is about 75%, the cytotoxicity is relatively low, and the HER2 coupled liposome can specifically target HER2 positive breast cancer cells; the flow cytometry result shows that after the targeted nano-liposome (virus peptide + diABZI) is added into the co-culture solution of the tumor cells and the PBMC, the proportion of B lymphocytes, NK cells and NK sample T cells is increased, and the co-cultured tumor cells are almost all killed in the experimental process.

The present invention belongs to the technical field of liposome pharmaceutical preparations, and specifically relates to a liposome and its application, a liposome preparation and its preparation method and application. The present invention provides a liposome, wherein the liposome membrane is modified with a glutathione group and an indole residue. The liposome provided by the present invention has excellent transmembrane transport ability, efficiently penetrates the blood-brain barrier and can be taken up by glioma cells, while exhibiting excellent endosomal escape properties, thereby effectively solving the technical problem of low blood-brain barrier permeability during the treatment of gliomas with temozolomide. At the same time, the present invention provides a liposome preparation that improves delivery efficiency and anti-tumor efficacy, has an inhibitory effect on both human and mouse glioma cells, shows a wide range of clinical application potential, and provides a new treatment plan for glioma patients with high efficiency and low toxicity.

The invention discloses a silybum marianum lipidosome applied to a liver protection tablet product and a preparation method, the silybum marianum lipidosome comprises a core material, and an internal wall material and an external wall material which sequentially wrap the surface of the core material; the core material is a silybum marianum extract; the inner wall material is modified soybean phospholipid; the outer wall material is a combination of starch sodium octenylsuccinate and polyethylene glycol. A lipidosome membrane embedding technology is adopted, the silybum marianum extract and soybean modified phospholipid are mixed according to a certain proportion and emulsified into a membrane, phospholipid bimolecular membrane embedding is formed, and then high-molecular compounds including starch sodium octenylsuccinate and polyethylene glycol are used as external wall materials to further include the phospholipid compound of the silybum marianum extract. The prepared lipidosome can be uniformly dispersed in an aqueous solution, the angle of repose is less than or equal to 40 degrees, the fluidity and the tabletting effect are better, the lipidosome is prepared into a sustained-release tablet, the bioavailability of the lipidosome can be improved, and the application of the lipidosome in a liver protection factor system can be expanded.

To provide a composition that enables simple preparation of liposomes having positively charged surfaces without raising safety concerns when used in cosmetics or topical skin preparations.SOLUTION: The present invention provides a composition for preparing liposomes having positively charged surfaces, the composition containing the following components (A) and (B), with the content of component (A) being 1 to 30 mass% and the content of component (B) being 70 to 99 mass%. The inventive composition for preparing liposomes enables simple preparation of liposomes having positively charged surfaces through dispersion in water. Component (A) is a liposome membrane component containing the following components (A1) and (A2): (A1) phospholipid; and (A2) sphingosine compound. Component (B) is a polyhydric alcohol.SELECTED DRAWING: None

The preparation method comprises the following steps: modifying lysine-proline-valine on phosphatidylserine active ester to obtain an anionic liposome, forming a liposome membrane by using the anionic liposome and cholesterol, and then uniformly coating a layer of liposome on the outer layer of each probiotic cell by using calcium ion mediation to realize single cell coating, so that a single cell is obtained; a probiotic oral delivery system is obtained. According to the probiotic oral delivery system, coating of probiotic single cells can be achieved, and meanwhile the survival rate of the probiotics is not affected by a coating method in the coating process. In addition, the probiotic oral delivery system provided by the invention can effectively improve the viability of the probiotics in gastrointestinal fluid, increase colonization of the probiotics in intestinal tracts, target inflammation parts in the intestinal tracts, effectively reverse DSS-induced colon injury, reduce inflammatory cell infiltration and recover crypts and mucous membrane layers; the expression of proinflammatory factors is obviously reduced, and the expression of anti-inflammatory factors is improved.

The invention provides a membrane phospholipid composition specific liposome for promoting eggshell mineralization and application thereof. The liposome membrane is prepared from the following components as raw materials: (a) core membrane phospholipid; (b) an acidic phospholipid and (c) a membrane stabilizing component; wherein the core membrane phospholipid comprises PC (Polycarbonate) and PE (Polyethylene); the acidic phospholipid is PS and / or PA; the membrane stabilizing component comprises at least one of methoxy polyethylene glycol modified phosphatidyl ethanolamine (DSPE-PEG), 1, 2-dimyristoyl-rac-glycerol-3-methoxy polyethylene glycol (DMG-PEG), 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)] (DOPE-PEG), and cholesterol (Cholesterol). Through specific combination of core membrane phospholipids (PC and PE) and acidic phospholipids (PS and / or PA), an initial mineralization microenvironment in a living body is successfully simulated. In-vitro mineralization test results show that the liposome can effectively promote formation and growth of calcium carbonate crystal nucleuses, has excellent performance on interfaces of eggshell membranes, silicon wafers and the like, and proves universality and effectiveness.

The present invention belongs to the technical field of anti-tumor drug preparations and relates to a long-acting fulvestrant liposome for injection and a method for preparing the same. The long-acting fulvestrant liposome for injection comprises a fulvestrant inclusion complex, a liposome membrane material, a lyoprotectant, and an aqueous medium. The long-acting fulvestrant liposome for injection exhibits good stability, high encapsulation efficiency, long-lasting sustained release, and high bioavailability.

The invention discloses a preparation method and anti-tumor application of a cantharidin-loaded ginsenoside nano-liposome, relates to the technical field of medicines, and in particular relates to a liposome which comprises phospholipid, ginsenoside and cantharidin. Ginsenoside and phospholipid are used as liposome membrane materials to wrap cantharidin, and the anti-tumor effect of the nano-liposome is improved. According to the preparation method disclosed by the invention, the nano-liposome particles with high entrapment efficiency are successfully obtained, the plaque and the ginsenoside are creatively combined for medication, and meanwhile, the use of cholesterol is reduced, so that the adverse stimulation reaction of the cholesterol to a human body is avoided.